Hagens Berman Seeks Lead Plaintiff in Corcept Securities Case After FDA Setback

Overview

• Hagens Berman is urging Corcept investors to seek lead-plaintiff status before an April 2026 court deadline in a securities class action in the Northern District of California.
• The case, brought by the Allegheny County Employees' Retirement System, alleges Corcept failed to tell investors that FDA staff warned in 2024 and early 2025 that relacorilant’s data did not show enough evidence of effectiveness.
• Plaintiffs also allege company leaders kept promoting Phase 3 results even though the FDA viewed the trial data as fundamentally flawed.
• Corcept disclosed an FDA Complete Response Letter in December 2025 that cited an insufficient evidentiary record for approval, and the stock fell about 50% that day, wiping out roughly $2.5 billion in market value.
• The lawsuit seeks recovery for investors who bought Corcept shares between October 31, 2024 and December 30, 2025, and firms are also inviting whistleblowers to share non-public information.